Chiara Federici
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$5.7MFederal grants as PI10 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
10 awards · $5.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 15, 2025 | NIH | STTR Phase II Manufacturing and Analytical Validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for Commercial Viability | $317K | BIOCHIP LABS, INC. |
| May 13, 2024 | NIH | STTR Phase II Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability (Administrative Supplement) | $71K | BIOCHIP LABS, INC. |
| May 6, 2024 | NIH | STTR Phase II Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability | $865K | BIOCHIP LABS, INC. |
| Mar 27, 2024 | NSF | STTR Phase II STTR Phase II: Optimized manufacturing and machine learning based automation of Endothelium-on-a-chip microfluidic devices for drug screening applications. | $1.1M | BIOCHIP LABS, INC. |
| May 1, 2023 | NIH | STTR Phase II Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability | $936K | BIOCHIP LABS, INC. with CASE WESTERN RESERVE UNIVERSITY |
| Mar 28, 2023 | NIH | STTR Phase II Endothelialized microfluidic assays for emerging therapies in sickle cell disease | $843K | BIOCHIP LABS, INC. |
| Apr 5, 2022 | NIH | STTR Phase II Endothelialized microfluidic assays for emerging therapies in sickle cell disease | $852K | BIOCHIP LABS, INC. |
| Mar 25, 2022 | NIH | STTR Phase II Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability | $260K | BIOCHIP LABS, INC. |
| Sep 1, 2021 | NIH | STTR Phase I Endothelialized microfluidic assays for emerging therapies in sickle cell disease | $257K | BIOCHIP LABS, INC. with CASE WESTERN RESERVE UNIVERSITY |
| Jun 1, 2021 | NSF | STTR Phase I STTR Phase I: Standardized and reproducible culture and activation of endothelial cells in microfluidic devices for drug screening applications | $256K | BIOCHIP LABS, INC. |
Peer ranks
Federal funding#233
Awards as PI#141
Patents#505
Companies
- BIOCHIP LABS, INC.Linked by awards · Medtech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.